Sign in
Taking people in SpainPhase 1

Tests elironrasib combinations in lung cancer with a RAS G12C mutation

Tests elironrasib with other cancer drugs in adults with RAS G12C-mutated lung cancer.

Key facts

Who runs it
Revolution Medicines Inc.
Where
A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, and Valencia, SpainSee the 13 sitesAlso in 4 other countries, 28 sites
Trial code
Registry title
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
Status
Recruiting
Phase
Phase 1
People taking part
330 people, planned
Started
17 Jul 2024
Expected to end
30 Oct 2027
Type of study
Interventional
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid tumor that has a RAS G12C change, including non-small cell lung cancer. People must have had earlier cancer treatment or be unable to tolerate regular treatments.

Age
18 years or older, or the legal age of consent.
Sex
All sexes can join.
Disease stage
Solid tumor with RAS G12C and at least one tumor lesion that can be measured.
Earlier treatment
Must have had prior cancer treatment or be unable to tolerate regular treatments. Cannot have taken targeted therapy for a KRAS mutation before.
Biomarker or test result
RAS G12C mutation.

Main reasons for not taking part

  • Primary brain or spinal cord tumor
  • Gastrointestinal problems that may affect absorption of elironrasib
  • Any major surgery in the last 4 weeks
  • Earlier targeted therapy for a KRAS mutation
  • Other medical conditions, medicines, foods or treatments that may interfere with the study drugs

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • ≥ Patients that are at least 18 years old, or legal age of consent. 2. Patients that have solid tumor with RAS-G12C. 3. Patients that have received prior cancer treatment or are not able to tolerate regular treatments. 4. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. 5. Patients that have adequate organ function (bone marrow, liver, kidney)

Who cannot take part

  • Participants that have primary brain and spinal cord tumor. 2. Participants thathave gastrointestinal problems that may affect absorption of elironrasib. 3. Participants thathad any major surgery in the last 4 weeks. 4. Participants thathave any other medical condition that may interfere with the study drugs. 5. Participants that have previously taken targeted therapy for KRAS mutation. 6. Participants that need other medicines, eat foods, or receive treatments that may interfere with the study drugs

Where in Spain

Also in 4 other countries, 28 sites

  • Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
  • Institut Catala d'OncologiaBadalona, SpainTaking people
  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Clinica Universidad de NavarraMadrid, SpainTaking people
  • Hospital Clínico San CarlosMadrid, SpainTaking people
  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
  • Hospital Universitario Ramón y CajalMadrid, SpainTaking people
  • Hospital Universitario Regional de MálagaMálaga, SpainTaking people
  • Clínica Universidad de navarraPamplona, SpainTaking people
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
  • Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the safety and tolerability of elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated solid tumors To define the RP2DS for elironrasib in combination with pembrolizumab, with or without daraxonrasib, with or without chemotherapy, in patients with advanced RAS G12C-mutated NSCLC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Plain-language title
Tests elironrasib combinations in lung cancer with a RAS G12C mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 October 2026